Jose Maymi, MD
Urology · Brownsville, TXNPI 1093717639
Payments from drug & device makers
Across 284 payments — averaging $47.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$3K
- Teleflex LLC$2K
- Boston Scientific$2K
- Astellas Pharma US Inc$2K
- Johnson & Johnson$856
- Sumitomo Pharma America, Inc.$533
- plus $4K from 29 others
What the payments were for
- Travel & lodging$5,39540%
- Food & beverage$7,37254%
- Education$8286%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 27 | $2,568 |
| Teleflex LLC | 13 | $2,460 |
| Boston Scientific | 13 | $1,870 |
| Astellas Pharma US Inc | 64 | $1,680 |
| Johnson & Johnson(2 entities) | 30 | $856 |
| Sumitomo Pharma America, Inc. | 22 | $533 |
| Bayer | 27 | $532 |
| Procept Biorobotics Corporation | 3 | $425 |
| Pfizer | 10 | $425 |
| KARL Storz Endoscopy-america | 2 | $196 |
| Foundation Medicine, Inc. | 4 | $169 |
| Myovant Sciences Inc. | 7 | $156 |
| Dendreon Pharmaceuticals LLC | 5 | $142 |
| Telix Pharmaceuticals | 2 | $135 |
| Endo Pharmaceuticals Inc. | 1 | $134 |
| Urovant Sciences Inc | 8 | $132 |
| Tolmar, Inc. | 6 | $126 |
| Myriad Genetic Laboratories, Inc. | 5 | $116 |
| Johnson And Johnson International | 1 | $112 |
| AbbVie | 1 | $100 |
| Cardiovascular Systems Inc. | 2 | $97 |
| Verity Pharmaceuticals Inc. | 5 | $82 |
| Antares Pharma, Inc. | 5 | $81 |
| 180 Medical, Inc. | 3 | $78 |
| Neotract Inc. | 2 | $70 |
| Ferring Pharmaceuticals Inc. | 2 | $56 |
| Alnylam Pharmaceuticals Inc. | 3 | $55 |
| Merck | 3 | $52 |
| Astellas Pharma Global Development | 1 | $39 |
| Convatec Inc. | 2 | $34 |
| Amgen | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Travere Therapeutics, Inc. | 1 | $16 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $16 |
| Dentsply IH Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TITAN$2,001
- UroLift$1,244
- UroLift System$926
- Solyx SIS System$818
- SPACEOAR VUE$571
- XTANDI$481
- AquaBeam Robotic System$375
- ILLUCCIX$233
- XARELTO$218
- XIAFLEX$134
- TALZENNA$127
- FOUNDATIONONE LIQUID CDX$125
- ORGOVYX$125
- ETHICON$112
- rezum Generator$109
- BOTOX$100
How this compares
$13,595 in reported general payments places this provider in the 75th percentile of 878 urology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 80 | $1,144,383 |
| ErleadaApalutamide | 54 | $823,020 |
| GemtesaVibegron | 608 | $544,627 |
| OrgovyxRelugolix | 175 | $451,132 |
| XgevaDenosumab | 69 | $214,484 |
| NubeqaDarolutamide | 13 | $176,878 |
| Abiraterone Acetate | 62 | $146,725 |
| PremarinEstrogens, Conjugated | 251 | $107,752 |
| MyrbetriqMirabegron | 94 | $99,494 |
| ProliaDenosumab | 59 | $97,146 |
| TrelstarTriptorelin Pamoate | 19 | $91,526 |
| Dutasteride | 1,391 | $67,061 |
| Tamsulosin Hcl | 2,369 | $31,649 |
| Solifenacin Succinate | 545 | $29,148 |
| XyostedTestosterone Enanthate | 31 | $18,488 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $1,680 | $1,243,878174 claims |
| Sumitomo Pharma America, Inc.Gemtesa, Orgovyx | $533 | $995,759783 claims |
| Johnson & JohnsonErleada | $856 | $823,02054 claims |
| AmgenXgeva, Prolia | $22 | $311,630128 claims |
| BayerNubeqa | $532 | $176,87813 claims |
| PfizerPremarin | $425 | $107,752251 claims |
| Verity Pharmaceuticals Inc.Trelstar | $82 | $91,52619 claims |
| Antares Pharma, Inc.Xyosted | $81 | $18,48831 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 878 urology providers in Texas.
Other urology in Brownsville
- Zvi SchiffmanHouston$17.8M
- Jose de la CerdaSan Antonio$9M
- Daniel SaltzsteinSan Antonio$5.8M
- Jose KaramHouston$5.7M
- Daniel ZainfeldSan Antonio$4.7M
- Brian MazzarellaLakeway$4.5M
- Andrew von EschenbachMontgomery$3.2M
- Raj SatkunasivamHouston$2.6M
- Alan SkolnickHouston$2.4M
- Homa PorterDallas$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.